New Drugs of 2010

Published Online: Wednesday, March 16, 2011

Pharmacy Times Continuing Education


New Drugs of 2010: Part 1

Michael A. Mancano , PharmD

New drugs were approved in 2010 for the treatment of a variety of conditions, including multiple sclerosis, stroke/systemic embolism, postmenopausal osteoporosis, and schizophrenia. In Part 1 of this CE lesson, the indications, mechanisms of action, drug interactions, and dosing of the following new agents are discussed:

• Dabigatran etexilate mesylate capsules (Pradaxa)
• Dalfampridine extended-release tablets (Ampyra)
• Denosumab injection (Prolia and Xgeva)
• Estradiol valerate and estradiol valerate/dienogest tablets (Natazia)
• Everolimus tablets (Zortress)
• Incobotulinumtoxina injection (Xeomin)
• Liraglutide rDNA injection (Victoza)
• Tocilizumab injection (Actemra)

Educational Objectives

Upon completion of this educational activity, participants should be able to:

1. Discuss the clinical indications of the new drugs approved by the FDA in 2010.
2. Explain the various mechanisms of action of the drugs discussed in this program.
3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
4. Identify the most common adverse reactions for the new drugs of 2010.
5. Cite the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Click here to view this lesson.


New Drugs of 2010: Part 2

Michael Mancano, PharmD

Part 2 of this lesson examines 8 more molecular entities that were approved by the FDA in 2010. These include:

• Alcaftadine ophthalmic colution (Lastacaft)
• Cabazitaxel injection (Jevtana)
• Ceftaroline fosamil injection (Teflaro)
• Fingolinod capsules (Gilenya)
• Lurasidone HCl tablets (Latuda)
• Pegloticase injection (Krystexxa)
• Tesamorelin acetate injection (Egrifta)
• Ulipristal acetate tablets (Ella)

Educational Objectives

Upon completion of this educational activity, participants should be able to:

1. Discuss the clinical indications of the new drugs approved by the FDA in 2010.
2. Explain the various mechanisms of action of the drugs discussed in this program.
3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
4. Identify the most common adverse reactions for the new drugs of 2010.
5. Cite the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Click here to view this lesson.